SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): June 1, 2016

REJUVEL BIO-SCIENCES, INC.

(Exact name of Company as specified in its charter)


Florida	0-53698	27-1116025
(State or other jurisdiction	(Commission File Number)	(IRS Employer
of Incorporation)		Identification Number)
	Chase Bank Building 150 SE 2nd Ave, Suite 403 Miami, Florida 33131
	(Address of principal executive offices)
	Phone: (800) 670-0448
	(Company’s Telephone Number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 – DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS

On June 1, 2016, Rejuvel Bio-Sciences, Inc., a Florida corporation, (the “Company”), with the approval of its board of directors and its majority shareholders by written consent in lieu of a meeting, removed Mr. John T. Stickler, as a Director and officer of the Company and terminated his Consulting Agreement.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Rejuvel Bio-Sciences, Inc.

Date: June 1, 2016

By: /s/ Charles J. Scimeca

Charles J. Scimeca

President and CEO

REJUVEL BIO-SCIENCES, INC. 8-K